Treating severe liver inflammation with emapalumab
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether the drug emapalumab can help children with severe liver inflammation that has not improved with steroids. It aims to reduce liver damage and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 1 year old.
- Your liver enzyme levels (ALT) must be very high (1000 or more).
- Your hepatitis (liver inflammation) has not improved with steroids, or you needed steroids to control it, or it came back after stopping them.
- Tests show your immune system T cells are overactive, which may be causing the liver inflammation.
- You cannot have advanced liver failure, other known causes of liver disease (like autoimmune hepatitis or Wilson disease), or certain active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, mycophenolate mofetil and prednisone, to treat moderate to severe liver inflammation caused by immunotherapy. The goal is to see if this treatment can help control the inflammation without needing long-term high-dose steroids.
This trial tests whether a medication called emapalumab can help children with severe aplastic anemia, a condition where the bone marrow stops making enough blood cells. It combines emapalumab with standard immune-suppressing therapy to try to improve blood cell counts.
This trial tests a drug called emapalumab to treat chronic gut inflammation (enteritis) in people with APECED, a rare immune disorder. It aims to see if the drug can help when other treatments haven't worked.
This trial studies a way to treat inflammation of the liver (hepatitis) caused by immune cancer medicines (anti-PD-1/PD-L1, sometimes with anti-CTLA-4) without relying on high-dose steroids. It may help reduce steroid side effects while keeping liver inflammation under control.
This Phase 2 study tests medicines that calm inflammation before the first stem cell transplant. It aims to make transplant safer and more effective for people with certain inherited immune regulation or inflammatory conditions.
This study tests whether a drug called emapalumab can help lung transplant recipients whose transplanted lungs are showing signs of rejection. The drug targets a specific immune protein (interferon gamma) that appears to drive this type of rejection.
Hear when a new Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.